Related Experiment Video
Updated: Mar 13, 2026
05:15
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
4.3K
Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody
Stefan W Metz1, Shaomin Tian1, Gabriel Hoekstra1
1Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America.
Plos Neglected Tropical Diseases
|October 21, 2016
Summary
Developing a new dengue vaccine, researchers used nanoparticle technology to display the dengue virus E-protein. This novel subunit vaccine platform shows promise for inducing stronger immune responses against dengue virus and other flaviviruses.
Area of Science:
- Virology
- Immunology
- Nanotechnology
- Vaccine Development
Background:
- Dengue virus (DENV) causes significant global health burden with over 350 million infections annually.
- Current dengue vaccine development faces challenges in achieving balanced immunity against all four serotypes and avoiding disease enhancement.
- Existing live-attenuated vaccines show only partial efficacy.
Purpose of the Study:
- To explore the potential of a particulate subunit vaccine using DENV E-protein displayed on nanoparticles.
- To evaluate a DENV2-nanoparticle vaccine candidate created with Particle Replication in Non-wetting Template (PRINT) technology.
- To assess the immunogenicity and antigen trafficking of the nanoparticle-based vaccine.
Main Methods:
- Expressed and purified the ectodomain of DENV2-E protein (sRecE).
- Adsorbed sRecE onto poly(lactic-co-glycolic acid) (PLGA) nanoparticles of varying sizes and shapes using PRINT technology.
- Conducted immunization studies comparing nanoparticle-adsorbed sRecE to soluble sRecE, analyzing antibody titers and neutralization capacity.
Main Results:
- PRINT nanoparticle-adsorbed sRecE induced higher IgG titers compared to soluble sRecE.
- A more potent DENV2-specific neutralizing antibody response was observed with the nanoparticle vaccine.
- Antigen trafficking studies revealed prolonged antigen bioavailability in lymph nodes, suggesting an antigen depot effect.
Conclusions:
- PRINT nanoparticles represent a promising platform for subunit vaccines against flaviviruses like dengue and Zika.
- Nanoparticle display of DENV E-protein enhances immunogenicity and neutralizing antibody responses.
- The PRINT technology facilitates the development of effective subunit vaccines by optimizing antigen presentation and bioavailability.
